BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251105T100000
DTEND;TZID=Europe/Stockholm:20251105T110000
DTSTAMP:20260511T053727
CREATED:20250922T082246Z
LAST-MODIFIED:20250923T075718Z
UID:189133-1762336800-1762340400@www.scilifelab.se
SUMMARY:From repurposing anti-parasitic drug to prodrugs towards cancer and lupus treatments
DESCRIPTION:Welcome to this DDD exit seminar\, hosted by the DDD platform in Navet\, Uppsala.  \n\n\n\nPlease register below for either on site or online attendance. \n\n\n\nRegistration\n\n\n\nSpeakers\n\n\n\nPeter Nygren is a senior physician in oncology\, specializing in gastrointestinal cancer\, at Akademiska hospital and a professor of oncology at the Department of Immunology\, Genetics and Pathology\, Uppsala University since 2005. Peter’s research focuses on the development and validation of treatment predictive tests\, the development of new cancer drugs and the improvement of the treatment of gastrointestinal cancer\, including through dietary interventions. \n\n\n\nMårten Fryknäs is an Associate Professor and Senior Lecturer in Experimental Clinical Pharmacology at the Department of Medical Sciences\, Uppsala University. His research focuses on the development of cell-based assays\, drug screening\, and mechanism deconvolution in two- and three-dimensional models. The overall aim is to identify new approaches for the pharmacological treatment of cancer. \n\n\n\nRolf Larsson has been a professor and senior physician in clinical pharmacology at the Department of Medical Sciences\, Uppsala University since 2000. Rolf Larsson’s research focus is cancer pharmacology\, where the identification and development of new cancer drugs is a main focus. “Repurposing” of already existing drugs for use in cancer treatment is another area of ​​interest. \n\n\n\nAbstract\n\n\n\nScientific breakthroughs sometimes arise from unexpected observations. In our case\, it was a seemingly random discovery: that the established antiparasitic drug mebendazole also had significant effects against cancer and autoimmune disease. This observation became the starting point for a research program supported by SciLifeLab Drug Discovery and Development\, which we hope will open up new therapeutic strategies. \n\n\n\nHowever\, a key problem was the pharmacokinetic limitations of mebendazole\, which had long hampered the ability to exploit its full potential. To address this\, a prodrug was developed with the aim of improving the bioavailability and the pharmacodynamic profile. In parallel\, systematic work was carried out to clarify the molecular mechanism of action that had long eluded us and which required both methodological innovations and interdisciplinary approaches to solve.After several years of study\, we were finally able to identify a mechanism that explains the observed effects and thus sheds light on new biological links between mebendazole and key disease processes. The results not only provide a new understanding of how the substance works\, but also point to the possibility of developing a whole new class of therapeutics. \n\n\n\nAt our DDD-exit seminar\, we will present the scientific journey from random observation to mechanistic explanation and discuss the implications our findings may have for the future treatment of cancer and autoimmune diseases. \n\n\n\n\n\n\n\nHost: Ylva Gravenfors ylva.gravenfors@scilifelab.se and SciLifeLab Drug Discovery and Development Platform
URL:https://www.scilifelab.se/event/from-repurposing-to-prodrugs-from-parasite-towards-cancer-and-lupus-treatment/
LOCATION:Navet\, SciLifeLab Uppsala\, SciLifeLab Uppsala\, BMC C11\, Husargatan 3\, Uppsala\, 75237\, Sweden
CATEGORIES:Event
END:VEVENT
END:VCALENDAR